ACTU (Actuate Therapeutics) EV-to-EBIT : (As of Dec. 11, 2024)

View and export this data going back to 2024. Start your Free Trial

What is Actuate Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Actuate Therapeutics's Enterprise Value is $170.22 Mil. Actuate Therapeutics does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Actuate Therapeutics's EV-to-EBIT at this moment.

The historical rank and industry rank for Actuate Therapeutics's EV-to-EBIT or its related term are showing as below:

ACTU' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.96 Med: 0 Max: 0
Current: -6.89

ACTU's EV-to-EBIT is ranked worse than
100% of 421 companies
in the Biotechnology industry
Industry Median: 9.9 vs ACTU: -6.89

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Actuate Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $0.00 Mil. Actuate Therapeutics does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Actuate Therapeutics's Earnings Yield (Joel Greenblatt) % at this moment.

Actuate Therapeutics EV-to-EBIT Historical Data

The historical data trend for Actuate Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actuate Therapeutics EV-to-EBIT Chart

Actuate Therapeutics Annual Data

Trend

Dec22

Dec23

EV-to-EBIT

Actuate Therapeutics Semi-Annual Data
	Dec22	Dec23
EV-to-EBIT	-	-

Competitive Comparison of Actuate Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Actuate Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actuate Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Actuate Therapeutics's EV-to-EBIT falls into.

Actuate Therapeutics EV-to-EBIT Calculation

Actuate Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	170.223	/
	=

Actuate Therapeutics (NAS:ACTU) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Actuate Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=		/	0
	=	%

Actuate Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Actuate Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Actuate Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actuate Therapeutics Inc (NAS:ACTU) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1751 River Run, Suite 400, Fort Worth, TX, USA, 76107

Website

https://www.actuatetherapeutics.com

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3?, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.